Drug intelligence / Profile preview

jincao zhike

Development stage: Unknown
Lead developer: Livzon Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Jincao Zhike is a novel Traditional Chinese Medicine (TCM) granule formulation developed by Beijing Langzhen Pharmaceutical Technology for the treatment of acute bronchitis. Classified as a Category 1.1 TCM new drug in China, it is specifically indicated for patients presenting with the wind-heat attacking the lungs syndrome. The formulation is derived from botanical extracts, primarily Kummerovia striata (Thunb.) Schindl., and is designed to exert antitussive, expectorant, and anti-inflammatory effects. Clinical development has progressed through Phase 3 trials in China, focusing on the relief of cough and associated respiratory symptoms by clearing heat, detoxifying, and resolving phlegm.

Brand names: Jincao Zhike Granules
Other names: Jincao Zhike Keli金草止咳颗粒

Beyond the preview

Go deeper on jincao zhike.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on jincao zhike.

Explore the full profile